Palatin Technologies (PTN) Tops Q2 EPS by 45c

Go back to Palatin Technologies (PTN) Tops Q2 EPS by 45c

Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

February 15, 2023 7:30 AM EST

Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Patient Enrollment on TrackTopline Results Currently Expected Mid-Calendar Year 2023Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Commenced First Patient Dosed Planned Interim Analysis Targeted for First Half Calendar Year 2023 Topline Results Currently Expected Second Half Calendar Year 2023Phase 2 Clinical Study of Bremelanotide in Patients with Diabetic Kidney Disease Complete Enrollment Targeted for Third Quarter Calendar Year 2023... More